Etoposide 100 Mg/5 Ml Fresenius 100 mg/5 mL Concentrate for solution for infusion
PDF Leaflet Revision Date: 02 September 2024
Clinical Summary
Quick overview from the medicine insert
Indication
Treatment of testicular and small cell lung tumors, and malignant lymphomas.
Dosage (summary)
50-100 mg/mu00b2/day for 5 days or 100-120 mg/mu00b2 on days 1, 3, 5 every 3-4 weeks.
Special Populations
- Renal impairment
- Hepatic impairment
Pregnancy & Breastfeeding
Contraindicated in pregnancy and breastfeeding; teratogenic potential.
Key Drug Interactions
- Ciclosporin
- Cisplatin
- Phenytoin
- Warfarin
Contraindications
- Hypersensitivity to etoposide
- Severe hepatic dysfunction
- Bone marrow depression
- Pregnancy
- Lactation
Common side effects
- Myelosuppression
- Nausea
- Vomiting
- Alopecia
- Hypotension
Counselling Points
- Avoid pregnancy during treatment
- Monitor for signs of infection
- Report any severe reactions immediately
Serious warnings
- Anaphylactic reactions
- Tumor lysis syndrome
- Secondary leukemia risk
Important Disclaimer
The Etoposide 100 Mg/5 Ml Fresenius 100 mg/5 mL Concentrate for solution for infusion professional information leaflet below is the property of Fresenius Kabi South Africa and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
